In the realm of endocrine diagnostics, Professor Brian Keevil is a beacon of innovation, leading the charge in revolutionizing the way we approach adrenal disorders. His work at Manchester University NHS Foundation Trust has shed light on the potential of salivary cortisone testing, a non-invasive method that could transform the diagnosis and monitoring of Cushing's syndrome and adrenal insufficiency. This article delves into Professor Keevil's insights, exploring the significance of salivary cortisone and its implications for the future of endocrine medicine.
A New Lens on Adrenal Disorders
Professor Keevil's journey into the world of salivary testing began with a simple yet profound realization: traditional blood-based testing is not always the most patient-friendly approach. Saliva, he explains, is a more convenient and accessible option, avoiding the discomfort of venepuncture and reducing the burden on both patients and healthcare services. This shift in perspective has opened up new avenues for the diagnosis and management of adrenal disorders.
The Power of Salivary Cortisone
The focus on salivary cortisone emerged from a clinical interest in free cortisol, the biologically active component that represents only 5% of circulating cortisol. When free cortisol enters the salivary gland, it is converted into cortisone, which is easier to measure accurately. This conversion makes salivary cortisone a more reliable biomarker, reflecting physiological cortisol exposure and providing a more linear relationship with serum cortisol levels.
Diagnosing Adrenal Insufficiency
Adrenal insufficiency, a potentially life-threatening condition, is often underdiagnosed due to nonspecific symptoms and the inconvenience of existing screening tests. Professor Keevil's research has shown that waking salivary cortisone collected at home can act as an effective first-line screening test. This non-invasive approach is safe, practical, and capable of reducing the need for more invasive investigations, making it a valuable tool in the early detection of adrenal insufficiency.
Cushing's Syndrome: A Complex Diagnosis
Cushing's syndrome, a challenging endocrine disorder, lacks a single definitive test. Professor Keevil's studies have demonstrated the superior performance of late-night salivary cortisone in patients with pituitary-dependent Cushing's disease. With a sensitivity of 95% and specificity of 100%, it outperformed other tests, making it a valuable addition to the diagnostic toolkit.
Salivary Cortisone and Dexamethasone Suppression Testing
The overnight dexamethasone suppression test is widely used to detect cortisol excess. Professor Keevil's research has shown that saliva samples can replace serum measurements in this setting, offering excellent diagnostic performance and convenience. This approach removes the need for patients to attend the hospital the morning after taking dexamethasone, making it a more patient-friendly option.
Metabolites and Their Role
The exploration of salivary dexamethasone metabolites has been another significant aspect of Professor Keevil's work. While direct measurement of salivary dexamethasone has not been particularly effective, measuring salivary 11-dehydrodexamethasone, a metabolite, provides better correlation with serum dexamethasone concentrations. This could become a valuable addition to future saliva-based diagnostic pathways, helping to identify patients with altered dexamethasone metabolism or absorption.
Mild Cortisol Excess: A Hidden Challenge
Mild autonomous cortisol secretion, a subtle yet significant issue, can be difficult to identify using conventional approaches. Professor Keevil's recent work suggests that late-night salivary cortisone may offer excellent discrimination between affected patients and controls, making it a valuable screening tool for identifying subtle cortisol excess before more severe disease develops.
The Future of Salivary Cortisone Testing
Professor Keevil's vision for the future of salivary cortisone testing is one of widespread adoption. He believes it will continue to gain traction as a routine outpatient and home-based test, offering excellent diagnostic performance and convenience. As more centers adopt LC-MS/MS methodologies, saliva-based steroid testing will become an increasingly important part of clinical practice, potentially reducing healthcare costs and improving access to endocrine testing.
In conclusion, Professor Brian Keevil's work on salivary cortisone testing is a testament to the power of innovation in endocrine medicine. His insights have the potential to transform the diagnosis and management of adrenal disorders, offering a more patient-friendly and accessible approach. As we look to the future, the continued development and adoption of salivary cortisone testing could pave the way for earlier intervention and improved outcomes for patients with endocrine disorders.
